APPLICATION
ANDA062655
TYPE
ANDA
ORIGINAL APPROVAL
1985-11-20
LATEST ACTION
2007-11-20
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
TAZIDIMEDiscontinued
CEFTAZIDIME 1GM/VIAL · INJECTABLE · INJECTION
TAZIDIMEDiscontinued
CEFTAZIDIME 2GM/VIAL · INJECTABLE · INJECTION
Approval history
2007-11-20Labeling · Supplement 13AP
1999-02-25Labeling · Supplement 6AP
1996-07-15Labeling · Supplement 10AP
1996-02-26Labeling · Supplement 9AP
1993-10-18Manufacturing (CMC) · Supplement 8AP
1992-10-30Manufacturing (CMC) · Supplement 7AP
1992-02-14Labeling · Supplement 4AP
1992-02-14Labeling · Supplement 5AP
1985-11-20OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.